Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: Results from a United Kingdom study

Diabetic Medicine

Volumn 22, Issue 5, 2005, Pages 554-562

  Guzder, R N ^a   Gatling, W ^a   Mullee, M A ^b   Mehta, R L ^b   Byrne, Christopher D ^b  

^a POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Clinical guidelines; Framingham equation; Risk factor; Type 2 diabetes; Validation

Indexed keywords

ADULT; AGED; ARTICLE; CALIBRATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; FEMALE; FRAMINGHAM EQUATION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIPID TRANSPORT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PROGNOSIS; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 17844366883     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01494.x     Document Type: Article

References (35)

1. National Institute of Clinical Excellence (NICE). Management of Type 2 diabetes - management of blood pressure and blood lipids (Guideline H). London: NICE, 2002.
2. Department of Health. National Service, Framework for Diabetes: Modern Standards and Service Models. London: Department of Health, 2003.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
4. ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
5. Colhoun HM, Thomason MJ, Mackness MI, Maton SM, Betteridge DJ, Durrington PN et al. Design of the Collaborative AtoRvastatin diabetes Study (CARDS) in patients with Type 2 diabetes. Diabet Med 2002; 19: 201-211.
6. Department of Health. National Service, Framework for Coronary Heart Disease, Modern Standards and Service Models. London: Department of Health, 2000.
7. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. Br Med J 2000; 320: 705-708.
8. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293-298.
9. Yeo WW, Yeo KR. Predicting CHD risk in patients with diabetes mellitus. Diabet Med 2001; 18: 341-344.
10. Byrne CD, Wild SH. Diabetes care needs evidence based interventions to reduce risk of vascular disease. Br Med J 2000; 320: 1554-1555.
11. Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type 2 diabetes (UKPDS 56). Clin Sci 2001; 101: 671-679.
12. American Diabetes Association. Dyslipidaemia management in adults with diabetes. Diabetes Care 2004; 27: S68-71.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-2497.
14. Gatling W, Guzder RN, Turnbull JC, Budd S, Mullee MA. The Poole Diabetes Study: how many cases of Type 2 diabetes are diagnosed each year during normal health care in a defined community? Diabetes Res Clin Pract 2001; S3: 107-112.
15. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991; 83: 356-362.
16. Rose G, Blackburn H. Cardiovascular Survey Methods. WHO Monograph Series 56. Geneva: World Health Organisation, 1968.
17. Hanley JA, McNeill BJ. The measure and use of the area under the receiver operating characteristic (ROC) curve. Radiology 2001; 143: 29-36.
18. D'Agostino RB, Griffith JL, Schmid CH, Terrin N. Measures for evaluating model performance. In: American Statistical Association 1996 Proceedings of the Section on Biometrics. Alexandria, VA: American Statistical Association, 1997: 253-258.
19. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons Inc., 1989.
20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with Type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
21. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with Type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. Br Med J 2002; 324: 939-942.
22. Folsom AR, Chambless EL, Duncan BB, Gilbert AC, Pankow JS. Atherosclerosis risk in communities investigators. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 2003; 26: 2777-2784.
23. European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
24. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979; 59: 8-13.
25. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996; 109: 224-231.
26. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346: 1467-71.
27. D'Agostino RB, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a Multiple Ethnic Groups investigation. J Am Med Assoc 2001; 286: 180-187.
28. Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart 2000; 84: 238-244.
29. Orford JL, Sesso HD, Stedman M, Gagnon D, Vokonas P, Gaziano MJ. A comparison of the Framingham and European Society of Cardiology coronary heart disease risk Prediction models in the Normative Aging Study. Am Heart J 2002; 144: 95-100.
30. Ramachandran S, French JM, Vanderpump MP, Croft P, Neary RH. Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. Br Med J 2000; 320: 676-677.
31. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 2003; 327: 1238-1239.
32. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
33. Wickus GG, Dukerschein RO. Serum-plasma differences in total cholesterol: what correction factor should be used? J Am Med Assoc 1992; 267: 234-235.
34. Cloey T, Bachorik PS, Becker D, Finney C, Lowry D, Sigmund W. Reevaluation of serum-plasma differences in total cholesterol concentration. J Am Med Assoc 1990; 263: 2788-2789.
35. Yudkin JS, Chaturvedi N. Developing risk stratification charts for diabetic and non-diabetic subjects. Diabet Med 1999; 16: 219-227.